Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10926992 | Cellular Immunology | 2015 | 9 Pages |
Abstract
Therapeutic protein products (TPPs) are of considerable value in the treatment of a variety of diseases, including cancer, hemophilia, and autoimmune diseases. The success of TPP mainly results from prolonged half-life, increased target specificity and decreased intrinsic toxicity compared with small molecule drugs. However, unwanted immune responses against TPP, such as generation of anti-drug antibody, can impact both drug efficacy and patient safety, which has led to requirements for increased monitoring in regulatory studies and clinical practice, termination of drug development, or even withdrawal of marketed products. We present an overview of current knowledge on immunogenicity of TPP and its impact on efficacy and safety. We also discuss methods for measurement and prediction of immunogenicity and review both product-related and patient-related risk factors that affect its development, and efforts that may be taken to mitigate it. Lastly, we discuss gaps in knowledge and technology and what is needed to fill these.
Keywords
NaBMHC IIPRCAmAbPBMCHMSATPPRIAIBDPIApure red cell aplasiaRheumatoid arthritisAnti-drug antibodyMonoclonal antibodyEfficacyRisk assessmentElectrochemiluminescence assaySafetyImmunogenicityInflammatory bowel diseaseEnzyme-linked immunosorbent assayELISASurface plasmon resonanceSPRradioimmunoassayPeripheral blood mononuclear cellDendritic cellPharmacokineticsMultiple sclerosisADATherapeutic proteinPredictionECLA
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Liusong Yin, Xiaoying Chen, Paolo Vicini, Bonita Rup, Timothy P. Hickling,